Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.

Abstract

Although metastatic breast cancer is responsive to radioimmunotherapy (RIT), a systemic targeted radiation modality, complete and permanent remissions are not typical with single-modality treatment. Antiangiogenic agents, which target normal, proliferating endothelial cells, have the potential to provide relatively nontoxic continuous inhibition of tumor… (More)

Topics

8 Figures and Tables

Cite this paper

@article{Burke2002CilengitideTO, title={Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.}, author={Patricia A. Burke and Sally J. Denardo and Laird Miers and Kathleen R. Lamborn and Siegfried Matzku and Gerald L. Denardo}, journal={Cancer research}, year={2002}, volume={62 15}, pages={4263-72} }